UP!
Akorn Pharmaceuticals (NASDAQ: AKRX) is an American generic pharmaceuticals manufacturer based in Lake Forest, Illinois. It is a component of the NASDAQ Biotechnology Index.
John Kapoor is not the founder but is a major shareholder since the 1990s.
Akorn acquired rival Hi-Tech Pharmacal in 2013.
In June 2015, it was reported that a hacker was trying to sell an Akorn customer database of more than 50,000 records. Akorn commented that "Although much of the information acquired is publicly available, we are in the process of notifying our valued customers about this incident".
In April 2017, Akorn was acquired by Fresenius for $4.3 billion.
| 2016-05-26 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-17 | Reiterated Rating | Guggenheim | Buy | $40.00 |
| 2016-05-17 | Reiterated Rating | RBC Capital | Outperform | $37.00 |
| 2016-05-17 | Reiterated Rating | Royal Bank Of Canada | Outperform | $37.00 |
| 2016-05-11 | Reiterated Rating | Jefferies Group | Buy | $35.00 |
| 2016-04-16 | Reiterated Rating | Leerink Swann | Market Perform | |
| 2016-03-23 | Reiterated Rating | Leerink Swann | Market Perform | $24.00 to $28.00 |
| 2016-03-23 | Lower Price Target | Susquehanna | Neutral | $32.00 to $30.00 |
| 2016-03-23 | Reiterated Rating | Jefferies Group | Buy | $43.00 to $35.00 |
| 2016-03-23 | Reiterated Rating | William Blair | Outperform | $58.00 to $36.00 |
| 2016-03-23 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-03-23 | Reiterated Rating | Piper Jaffray Cos. | Hold | |
| 2016-03-22 | Lower Price Target | S&P Equity Research | $25.98 to $21.97 | |
| 2016-03-22 | Reiterated Rating | Guggenheim | Buy | $40.00 |
| 2016-03-22 | Reiterated Rating | Craig Hallum | Buy | |
| 2016-03-21 | Lower Price Target | Raymond James | $53.00 to $30.00 | |
| 2016-03-21 | Lower Price Target | Nomura | Buy | $46.00 to $42.00 |
| 2016-03-21 | Lower Price Target | Raymond James Financial Inc. | $53.00 to $30.00 | |
| 2016-03-21 | Lower Price Target | Nomura Holdings Inc. | Buy | $46.00 to $42.00 |
| 2016-03-18 | Lower Price Target | Deutsche Bank | Buy | $40.00 to $33.00 |
| 2016-03-18 | Lower Price Target | Deutsche Bank AG | Buy | $40.00 to $33.00 |
| 2016-03-16 | Reiterated Rating | Leerink Swann | Market Perform | $41.00 to $24.00 |
| 2016-03-14 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $50.00 to $45.00 |
| 2016-02-25 | Reiterated Rating | Nomura | Buy | $46.00 |
| 2016-02-13 | Reiterated Rating | RBC Capital | Buy | |
| 2016-02-12 | Lower Price Target | RBC Capital | Outperform | $52.00 to $37.00 |
| 2016-02-01 | Reiterated Rating | Guggenheim | Buy | $60.00 |
| 2016-01-30 | Reiterated Rating | RBC Capital | Outperform | $52.00 |
| 2016-01-28 | Reiterated Rating | Nomura | Buy | $46.00 |
| 2016-01-15 | Reiterated Rating | Craig Hallum | Buy | |
| 2016-01-14 | Reiterated Rating | Nomura | Buy | $46.00 |
| 2016-01-13 | Reiterated Rating | Deutsche Bank | Buy | $40.00 |
| 2016-01-13 | Reiterated Rating | RBC Capital | Outperform | $52.00 |
| 2015-12-15 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-12-02 | Upgrade | Nomura | Neutral to Buy | $44.00 to $46.00 |
| 2015-11-06 | Reiterated Rating | RBC Capital | Outperform | $65.00 to $52.00 |
| 2015-11-06 | Lower Price Target | Jefferies Group | Buy | $56.00 to $43.00 |
| 2015-09-29 | Initiated Coverage | Nomura | Neutral | $44.00 |
| 2015-09-25 | Reiterated Rating | Leerink Swann | Market Perform | $50.00 to $41.00 |
| 2015-09-09 | Initiated Coverage | JMP Securities | Market Perform | |
| 2015-07-20 | Initiated Coverage | Susquehanna | Neutral | $48.00 |
| 2015-06-03 | Initiated Coverage | Raymond James | Outperform | $53.00 |
| 2015-05-03 | Reiterated Rating | William Blair | Outperform | $58.00 |
| 2015-04-27 | Reiterated Rating | Deutsche Bank | Buy | |
| 2015-04-27 | Downgrade | Piper Jaffray | Overweight to Neutral | $66.00 to $53.00 |
| 2015-04-20 | Set Price Target | Jefferies Group | Buy | $56.00 |
| 2015-04-15 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $61.00 |
| 2015-04-07 | Initiated Coverage | Deutsche Bank | Buy | $55.00 |
| 2015-03-27 | Initiated Coverage | Avondale Partners | Outperform | $56.00 |
| 2015-03-10 | Reiterated Rating | Jefferies Group | Buy | $59.00 to $56.00 |
| 2015-02-27 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2015-02-27 | Boost Price Target | Leerink Swann | Market Perform | $42.00 to $55.00 |
| 2015-02-27 | Reiterated Rating | Jefferies Group | Buy | $49.00 to $50.00 |
| 2015-02-27 | Boost Price Target | WallachBeth Capital | Buy | $43.00 to $65.00 |
| 2015-02-26 | Set Price Target | Guggenheim | Buy | $60.00 |
| 2015-02-04 | Initiated Coverage | Sterne Agee CRT | Buy | $52.00 |
| 2015-01-26 | Boost Price Target | Piper Jaffray | Overweight | $45.00 to $55.00 |
| 2015-01-20 | Boost Price Target | Jefferies Group | Buy | $44.00 to $49.00 |
| 2014-12-09 | Initiated Coverage | William Blair | Average to Outperform | $50.00 |
| 2014-11-13 | Upgrade | CRT Capital | Fair Value to Buy | $46.00 |
| 2014-10-29 | Initiated Coverage | CRT Capital | Fair Value | $46.00 |
| 2014-10-14 | Initiated | WallachBeth | Buy | $43 |
| 2014-10-14 | Initiated Coverage | WallachBeth Capital | Buy | $43.00 |
| 2014-09-29 | Upgrade | RBC Capital | Sector Perform to Outperform | $36.00 to $45.00 |
| 2014-09-04 | Boost Price Target | Leerink Swann | $26.00 to $40.00 | |
| 2014-08-06 | Boost Price Target | Jefferies Group | $31.00 to $40.00 | |
| 2014-08-06 | Boost Price Target | Piper Jaffray | Overweight | $33.00 to $45.00 |
| 2014-08-06 | Boost Price Target | RBC Capital | Sector Perform | $26.00 to $36.00 |
| 2014-07-01 | Boost Price Target | Needham & Company LLC | $30.00 to $36.50 | |
| 2014-06-05 | Reiterated Rating | Bank of America | Buy | $33.00 to $28.00 |
| 2014-06-02 | Initiated Coverage | Goldman Sachs | Neutral | $27.00 |
| 2014-05-15 | Reiterated Rating | Jefferies Group | Buy | $28.00 |
| 2014-05-13 | Reiterated | Needham | Buy | $28 to $30 |
| 2014-05-13 | Boost Price Target | Needham & Company LLC | Buy | $28.00 to $30.00 |
| 2014-05-13 | Boost Price Target | Guggenheim | Buy | $30.00 to $33.00 |
| 2014-05-07 | Reiterated Rating | Jefferies Group | Buy | $28.00 |
| 2014-04-29 | Reiterated Rating | Jefferies Group | Buy | $28.00 |
| 2014-04-21 | Initiated Coverage | Jefferies Group | Buy | $28.00 |
| 2014-03-04 | Reiterated | Needham | Buy | $25 to $28 |
| 2014-03-04 | Boost Price Target | Needham & Company LLC | Buy | $25.00 to $28.00 |
| 2014-01-08 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2014-01-07 | Initiated Coverage | RBC Capital | Sector Perform to Sector Perform | $27.00 |
| 2013-11-18 | Boost Price Target | Needham & Company LLC | Buy | $23.00 to $25.00 |
| 2013-11-06 | Boost Price Target | Needham & Company LLC | Buy | $22.00 to $23.00 |
| 2013-10-07 | Initiated Coverage | Ned Davis Research | Neutral | |
| 2013-09-26 | Initiated Coverage | Guggenheim | Buy | |
| 2013-08-28 | Reiterated | Needham | Buy | $18 to $22 |
| 2013-08-07 | Reiterated | Needham | Buy | $16 to $18 |
| 2013-01-28 | Initiated | RBC Capital Mkts | Sector Perform | $14 |
| 2012-07-23 | Downgrade | Deutsche Bank | Buy to Hold | $15 to $14 |
| 2012-02-23 | Reiterated | Deutsche Bank | Buy | $13 to $15 |
| 2012-01-18 | Reiterated | Needham | Buy | $12 to $13 |
| 2011-12-23 | Reiterated | Deutsche Bank | Buy | $11 to $13 |
| 2011-09-16 | Initiated | Deutsche Bank | Buy | $11 |
| 2010-11-08 | Reiterated | Rodman & Renshaw | Mkt Outperform | $5 to $8 |
| 2010-07-15 | Initiated | Rodman & Renshaw | Mkt Outperform | $5 |
| 2009-02-26 | Reiterated | Credit Suisse | Outperform | $6 to $3 |
| 2007-03-27 | Reiterated | Friedman Billings | Outperform | $7.50 to $8.50 |
| 2016-05-26 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-17 | Reiterated Rating | Guggenheim | Buy | $40.00 |
| 2016-05-17 | Reiterated Rating | RBC Capital | Outperform | $37.00 |
| 2016-05-17 | Reiterated Rating | Royal Bank Of Canada | Outperform | $37.00 |
| 2016-05-11 | Reiterated Rating | Jefferies Group | Buy | $35.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AKRX 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| BONACCORSI JOSEPH Sr. VP and General Counsel | 0.50% (523546) | AKRX / |
| KAPOOR JOHN N | 0.49% (505987) | AKRX / INSY / |
| RAI RAJAT CEO | 0.42% (439738) | AKRX / |
| KUTINSKY BRUCE COO, US Operations | 0.32% (333246) | AKRX / |
| Silverberg Mark M Exec VP, Ops & Global Quality | 0.25% (256522) | AKRX / |
| Dick Timothy A Chief Financial Officer | 0.24% (246311) | AKRX / |
| JOHNSON RONALD M | 0.15% (156203) | AKRX / |
| MEYER STEVEN J | 0.10% (107394) | AKRX / INSY / |
| Portwood Duane A Executive Vice President & CFO | 0.09% (97696) | AKRX / |
| WEINSTEIN ALAN D | 0.08% (80795) | ADGE / AKRX / |
| Tambi Brian | 0.06% (65264) | AKRX / INSY / |
| Graves Adrienne L | 0.05% (46938) | AKRX / TEAR / |
| Kafer Jonathan EVP, Sales and Marketing | 0.04% (44324) | AKRX / |
| Sabat John R Senior VP, National Accounts | 0.04% (40256) | AKRX / |
| ABRAMOWITZ KENNETH | 0.04% (39782) | AKRX / |
| Lichter Steven EVP, Pharmaceutical Operations | 0.03% (31106) | AKRX / |
| Pollard Randall E. CAO & Interim CFO | 0.03% (28187) | AKRX / |
| RAPPUHN TERRY ALLISON | 0.03% (27438) | AKRX / QHC / SKH / SPAN / |
UM